E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Novel Advances and Approaches in Biomedical Materials Based on Calcium Phosphates"

A special issue of Materials (ISSN 1996-1944).

Deadline for manuscript submissions: 30 April 2018

Special Issue Editor

Guest Editor
Associate Professor Michael R. Mucalo

School of Science, University of Waikato, Hamilton 3216, New Zealand
Website | E-Mail
Interests: biomaterials; calcium phosphate chemistry; metal colloids; IR spectroelectrochemistry; pseudohalide-containing electrolytes; application of IR spectroscopy; drug delivery

Special Issue Information

Dear Colleagues,

Research into the use of calcium phosphates in the development and clinical application of biomedical materials has been a significantly diverse activity by a wide range of scientists, engineers and medical practitioners, among others. The field of research in this area can hence be truly defined as interdisciplinary and much interesting work leading to imaginative and innovative solutions for the improvement of health outcomes continues.

It is the intention of this Special Issue to summarize a wide selection of the current advances in this area. We thus invite contributions to this issue in the form of original articles, review articles, research notes and short communications from various areas of this scientific discipline. Areas of interest that could be covered are contributions based on uses of natural by products to form potential biomaterials, novel composites of calcium phosphates with other materials, chemical manipulations of calcium phosphates that lead to novel biomaterials, studies advancing further the cell biology surrounding the incorporation of calcium phosphate biomaterials, engineering/biomechanical aspects of using calcium phosphate biomaterials and human or animal clinical studies involving calcium phosphates. Studies on novel approaches to characterization to study these materials would also be of interest.  Other types of contribution welcomed would be from those involved with regulating the use of calcium phosphate biomaterials. Hence, we invite, scientists, engineers, doctors, and medical device regulators to submit articles of interest.

It is hoped that this Special Issue will be enriched with these very diverse topics that provide an overall picture of advancements in this area.

We look forward to your contributions. Each article will be subject to rigorous peer review.

Associate Professor Michael R. Mucalo

Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • calcium phosphate
  • hydroxyapatite
  • characterisation
  • regulation
  • natural matrices
  • clinical use
  • orthopedics
  • xenografts
  • medical devices

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Enhancement of Osteoblastic-Like Cell Activity by Glow Discharge Plasma Surface Modified Hydroxyapatite/β-Tricalcium Phosphate Bone Substitute
Materials 2017, 10(12), 1347; doi:10.3390/ma10121347
Received: 5 October 2017 / Revised: 11 November 2017 / Accepted: 21 November 2017 / Published: 23 November 2017
PDF Full-text (4206 KB) | HTML Full-text | XML Full-text | Supplementary Files
Glow discharge plasma (GDP) treatments of biomaterials, such as hydroxyapatite/β-tricalcium phosphate (HA/β-TCP) composites, produce surfaces with fewer contaminants and may facilitate cell attachment and enhance bone regeneration. Thus, in this study we used argon glow discharge plasma (Ar-GDP) treatments to modify HA/β-TCP particle
[...] Read more.
Glow discharge plasma (GDP) treatments of biomaterials, such as hydroxyapatite/β-tricalcium phosphate (HA/β-TCP) composites, produce surfaces with fewer contaminants and may facilitate cell attachment and enhance bone regeneration. Thus, in this study we used argon glow discharge plasma (Ar-GDP) treatments to modify HA/β-TCP particle surfaces and investigated the physical and chemical properties of the resulting particles (HA/β-TCP + Ar-GDP). The HA/β-TCP particles were treated with GDP for 15 min in argon gas at room temperature under the following conditions: power: 80 W; frequency: 13.56 MHz; pressure: 100 mTorr. Scanning electron microscope (SEM) observations showed similar rough surfaces of HA/β-TCP + Ar-GDP HA/β-TCP particles, and energy dispersive spectrometry analyses showed that HA/β-TCP surfaces had more contaminants than HA/β-TCP + Ar-GDP surfaces. Ca/P mole ratios in HA/β-TCP and HA/β-TCP + Ar-GDP were 1.34 and 1.58, respectively. Both biomaterials presented maximal intensities of X-ray diffraction patterns at 27° with 600 a.u. At 25° and 40°, HA/β-TCP + Ar-GDP and HA/β-TCP particles had peaks of 200 a.u., which are similar to XRD intensities of human bone. In subsequent comparisons, MG-63 cell viability and differentiation into osteoblast-like cells were assessed on HA/β-TCP and HA/β-TCP + Ar-GDP surfaces, and Ar-GDP treatments led to improved cell growth and alkaline phosphatase activities. The present data indicate that GDP surface treatment modified HA/β-TCP surfaces by eliminating contaminants, and the resulting graft material enhanced bone regeneration. Full article

Figure 1

Back to Top